Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors

Gene Therapy

Volumn 22, Issue 3, 2015, Pages 257-266

  Essex, S ^a   Navarro, G ^a   Sabhachandani, P ^a   Chordia, A ^a   Trivedi, M ^a   Movassaghian, S ^a   Torchilin, V P ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; DRUG CARRIER; PHOSPHOLIPID; POLYETHYLENEIMINE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROGRAFTS; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; P-GLYCOPROTEINS; PHOSPHOLIPIDS; POLYETHYLENEIMINE; RNA, SMALL INTERFERING;

EID: 84924557768     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.97     Document Type: Article

References (64)

1. Perez E. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 2009; 114: 195-201.
2. Wind NS, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011; 2011: 1-12.
3. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Ampli fication of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316: 817-819.
4. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4: 389-398.
5. Hilary Thomas HMC. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10: 150-165.
6. Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013; 31: 1397-1407.
7. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. In: Zhou J (eds). Multi-Drug Resistance in Cancer. Humana Press: New Jersey, USA, 2010, pp 341-358.
8. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006; 580: 2903-2909.
9. Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013; 13: 326-346.
10. Lee C. Reversing agents for ATP-binding cassette drug transporters. In: Zhou J (eds). Multi-Drug Resistance in Cancer. Humana Press: New Jersey, USA, 2010, pp 325-340.
11. Abbasi M, Lavasanifar A, Uludə H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 2013; 33: 33-53.
12. Stege A, Krühn A, Lage H. Overcoming multidrug resistance by RNA interference. In: Zhou J (eds). Multi-Drug Resistance in Cancer . Humana Press: New Jersey, USA, 2010, pp 447-465.
13. Kruehn AWA, Fruehauf J, Lage H. Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells. Cell Cycle 2009; 8: 3349-3354.
14. Xia Z, Zhu Z, Zhang L, Royal C, Liu Z, Chen Q et al. Specific reversal of MDR1/P-gpdependent multidrug resistance by RNA interference in colon cancer cells. Oncol Rep 2008; 20: 1433-1439.
15. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliver Rev 2007; 59: 75-86.
16. Won YY, Sharma R, Konieczny SF. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J Control Release 2009; 139: 88-93.
17. Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, Andresen TL. The possible 'proton sponge ' effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther 2013; 21: 149-157.
18. Zhong D, Jiao Y, Zhang Y, Zhang W, Li N, Zuo Q et al. Effects of the gene carrier polyethyleneimines on structure and function of blood components. Biomaterials 2013; 34: 294-305.
19. Kunath K, von Harpe A, Fischer D, Petersen H, Bickel U, Voigt K et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003; 89: 113-125.
20. Godbey WT, Wu KK, Mikos AG. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 1999; 45: 268-275.
21. Navarro G, Sawant R, Essex S, Tros de Ilarduya C, Torchilin V. Phospholipid- polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res 2011; 1: 25-33.
22. Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C, Torchilin VP. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) 2012; 7: 65-78.
23. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63: 131-135.
24. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
25. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biophar 2009; 71: 409-419.
26. Sawant RR, Sriraman SK, Navarro G, Biswas S, Dalvi RA, Torchilin VP. Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials 2012; 33: 3942-3951.
27. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly (ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005; 13: 73-80.
28. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. In: Coligan JE, Bierer BE, Margulies DH, Shevach EM, Strober W (eds). Current Protocols in Immunology. John Wiley and Sons, Inc: New York, NY, USA, 2001.
29. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002; 98: 463-469.
30. Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N et al. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. Cancer Res 2002; 62: 2327-2331.
31. Fu L, Zhang Y, Liang Y, Yang X, Pan Q. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002; 38: 418-426.
32. Lu H-L, Syu W-J, Nishiyama N, Kataoka K, Lai P-S. Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo. J Control Release 2011; 155: 458-464.
33. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J 2010; 12: 171-180.
34. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005; 103: 405-418.
35. Gao Y, Chen L, Zhang Z, Chen Y, Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 2011; 32: 1738-1747.
36. Jiang J, Yang S, Wang J, Yang L, Xu Z, Yang T et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010; 76: 170-178.
37. Boone L, Meyer D, Cusick P, Ennulat D, Bolliger AP, Everds N et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 2005; 34: 182-188.
38. Kratz F, Warnecke A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012; 164: 221-235.
39. Lu D, Wientjes MG, Lu Z, Au JL-S. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 2007; 322: 80-88.
40. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009; 27: 643-651.
41. Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013; 7: 994-1005.
42. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmcol 2009; 63: 711-722.
43. Gebhart CL, Sriadibhatla S, Vinogradov S, Lemieux P, Alakhov V, Kabanov AV. Design and formulation of polyplexes based on pluronic-polyethylenimine conjugates for gene transfer. Bioconjug Chem 2002; 13: 937-944.
44. Shen J, Yin Q, Chen L, Zhang Z, Li Y. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012; 33: 8613-8624.
45. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010; 18: 1650-1656.
46. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 2008; 129: 107-116.
47. Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(- PEG)/siRNA complexes. Toxicol Appl Pharm 2009; 236: 97-108.
48. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly (ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 2009; 138: 148-159.
49. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Therapy 2006; 13: 541-552.
50. Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA 2012; 109: 3137-3142.
51. Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM et al. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009; 124: 465-472.
52. Grosse PY, Bressolle F, Pinguet F. Antiproliferative effect of methyl-betacyclodextrin in vitro and in human tumour xenografted athymic nude mice. Br J Cancer 1998; 78: 1165-1169.
53. Li Q, Lv S, Tang Z, Liu M, Zhang D, Yang Y et al. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation. Int J Pharm 2014; 471: 412-420.
54. Abbasi M, Aliabadi HM, Moase EH, Lavasanifar A, Kaur K, Lai R et al. siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice. Pharm Res 2011; 28: 2516-2529.
55. Yin Q, Shen J, Chen L, Zhang Z, Gu W, Li Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012; 33: 6495-6506.
56. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010; 31: 358-365.
57. Xiong X-B, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011; 5: 5202-5213.
58. Li J, Wang Y, Zhu Y, Oupicky D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release 2013; 172: 589-600.
59. Mosure KW, Henderson AJ, Klunk LJ, Knipe JO. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96- doxorubicin immunoconjugate (BMS 182248). Cancer Chemother Pharmcol 1997; 40: 251-258.
60. Mao S, Neu M, Germershaus O, Merkel O, Sitterberg J, Bakowsky U et al. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/ siRNA polyplexes. Bioconjug Chem 2006; 17: 1209-1218.
61. Wu H, Hait WN, Yang J-M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63 : 1515-1519.
62. Pakunlu RI, Cook TJ, Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 2003; 20 : 351-359.
63. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 2008; 3: 761-776.
64. Li S-D, Chen Y-C, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2007; 16: 163-169.